While the virus hasn’t made a sustained leap into humans, vaccines and treatments are being developed ahead of an outbreak.

Ab&B Bio-Tech has joined the stacked roster of drug developers queuing up to go public in Hong Kong, filing the paperwork for an IPO to fund development of vaccines that could compete with companies ...

GSK has reported positive interim results from its Phase II trial of mRNA-based multivalent influenza vaccine candidate, ...

GSK plc GSK reported fourth-quarter 2024 core earnings of 59 cents per American depositary share (ADS), which beat the Zacks ...

American depositary shares of GSK jumped more than 8% Wednesday after the drugmaker reported better-than-expected quarterly results and boosted its long-term sales forecast. Sales of vaccines against ...

GSK’s influenza vaccine, Fluarix Quadrivalent, has been approved by the US FDA for the immunisation of adults and children aged three years and older to help prevent disease caused by seasonal ...

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory infections, paying €400 million ($429 million) upfront for global rights to its influenza and COVID ...

The European Commission has just approved the prepandemic vaccine Prepandrix from GlaxoSmithKline ... application for its own prepandemic flu vaccine, Aflunov. The European Medicines Agency's ...

The FDA will require GSK and Pfizer to include on the label ... on the order of one to two additional GBS cases per million doses of flu vaccine administered,” according to the CDC.

influenza, malaria, and others. In 2022, GSK’s 12 manufacturing sites in eight countries produced and delivered more than 500 million vaccine doses—one and a half million vaccine doses daily.